Histologically proven adenocarcinoma of the prostate
Prostate cancer proven by histopathology
Histologically-proven prostate adenocarcinoma\r\n* Gleason score 6-10 based on a review of the prostate core biopsies at Moffitt Cancer Center
Biopsy proven prostate cancer
Histologically proven adenocarcinoma of the prostate diagnosed (with ?10 core biopsy) within 6 months of screening. The biopsy that was used for this diagnosis must be submitted for central pathology review.
Histologically proven prostate adenocarcinoma:\r\n* Gleason score 2-7 \r\n* Biopsy within one year of date of registration
Patients with histopathologically proven adenocarcinoma of the prostate
Have biopsy proven carcinoma of the prostate
Histologically proven adenocarcinoma of the prostate
Histologically proven adenocarcinoma of the prostate
Histologically or cytologically proven diagnosis of prostate cancer.
Histologically proven adenocarcinoma of the prostate
Histologically or cytologically proven prostate carcinoma
Histologically proven adenocarcinoma of the prostate
Histologically proven adenocarcinoma of the prostate
Histologically or cytologically proven adenocarcinoma of the prostate; if pathology is unavailable, the principal investigator (PI) may also make a determination of prostate cancer based on unequivocal clinic data
Patient must have non-metastatic, biopsy proven prostate cancer
Patient had a prostate biopsy performed by Dr. Mark with the Artemis device and has adenocarcinoma of the prostate
Biopsy proven adenocarcinoma of the prostate (using a IMAGE-guided 14+ core mapping biopsy), and targeted cores as needed obtained up to 6 months prior to scheduled treatment.
COHORT I: Biopsy proven adenocarcinoma of the prostate
Histopathology proven prostate cancer.
Histopathologically proven prostate cancer (PCa)
Histopathological proven prostate adenocarcinoma
Pathologically proven prostate adenocarcinoma
Biopsy-proven prostate adenocarcinoma
Biopsy proven prostate adenocarcinoma
Histopathologically proven prostate adenocarcinoma
SUB-STUDY I: Newly diagnosed prostate cancer pathologically proven by prostate biopsy
SUB-STUDY II: Prostate cancer pathologically proven by prostate biopsy
SUB-STUDY III: Prostate cancer pathologically proven by prostate biopsy
Biopsy proven prostate adenocarcinoma
Histopathological proven prostate adenocarcinoma
Biopsy proven prostate adenocarcinoma
Biopsy-proven prostate cancer
Not otherwise eligible for prostate biopsy
Have biopsy proven carcinoma of the prostate
Biopsy proven prostate adenocarcinoma
Biopsy proven prostate adenocarcinoma
Biopsy proven adenocarcinoma of the prostate
At least 4 weeks after most recent prostate biopsy
Males with known (biopsy?confirmed) primary adenocarcinoma of the prostate undergoing active surveillance scheduled for prostate biopsy (population group B)
Biopsy proven, clinical stage 1-3 prostate carcinomas
Patients who had > 1 prior prostate biopsy
Biopsy proven prostate adenocarcinoma
Histopathological proven prostate adenocarcinoma
Prostate adenocarcinoma diagnosed by biopsy within 12 months prior to study registration
Prior prostate biopsy
